stockportfolio.pro
Stocks / LH vs MRNA
LH vs MRNA
Labcorp Holdings Inc. and Moderna, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Labcorp Holdings Inc. (LH) | Moderna, Inc. (MRNA) | |
|---|---|---|
| Market cap | $21.7B | $20.7B |
| Revenue (latest FY) | $13.95B | $1.94B |
| Net income (latest FY) | $876.50M | $-2.82B |
| Revenue growth (5y CAGR) | -0.0% | 19.3% |
| Net margin | 6.3% | -145.2% |
| Return on equity | 10.2% | -32.6% |
| P/E ratio | 23.5 | — |
| Dividend yield | 1.1% | — |
| Profitable years (of last 10) | 10 | 2 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open LH — free Open MRNA — freeFrequently asked questions
Which is bigger, LH or MRNA?
Labcorp Holdings Inc. is larger by market capitalization — $21.7B versus $20.7B.
Which grows faster, LH or MRNA?
Over the last five fiscal years, Moderna, Inc. grew revenue faster — 19.3%/yr versus -0.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.